ClinicalTrials.gg
RecruitingNCT07122518REALPASSUpdated Oct 2, 2026

Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis

An observational study in Pulmonary Artery Stenosis, sponsored by Cordis US Corp.. Recruiting at 8 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Cordis US Corp. · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 2, 2026Now RecruitingFirst site in United States+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Sex
All
01

Study summary

The purpose of the clinical investigation is to characterize clinical outcomes and to assess the real-world use of the commercial PALMAZ MULLINS XD™ Pulmonary Stent.

Read the detailed description

The clinical study is a prospective, single-arm, multi-center, post-approval study of all consecutive subjects treated with the PALMAZ MULLINS XD™ Pulmonary Stent. The study will enroll a minimum of 35 subjects and a maximum of 75 subjects in up to 11 U.S sites or until the end of the 2-year enrollment period has been reached, whichever comes first.

The study will collect the performance and safety data of the PALMAZ MULLINS XD™ Pulmonary Stent through time of hospital discharge.

02

Conditions studied

  • Pulmonary Artery Stenosis

Keywords

  • pulmonary artery stenosis
  • Pulmonary Artery Stenting
  • PALMAZ MULLINS XD Pulmonary Stent
03

In context

Lead sponsor

Cordis US Corp. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with pulmonary artery stenosis who are candidates for treatment with the PALMAZ MULLINS XD™ Pulmonary Stent according to clinical guidelines and/or the operators' judgement will be eligible for enrollment in this study.

Eligibility criteria

- Subjects *should* meet criteria as per the list of indications/ in the Instructions for Use, though all subjects treated with the PALMAZ MULLINS XD™ Pulmonary Stent will be considered eligible and enrolled.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No

Groups and cohorts

  • Palmaz Mullins XD™ Treatment

    All enrolled subjects are treated with the PALMAZ MULLINS XD™ Pulmonary Stent

    Device: PALMAZ MULLINS XD™ Pulmonary Stent

Interventions

  • DevicePALMAZ MULLINS XD™ Pulmonary Stent

    The PALMAZ MULLINS XD™ Pulmonary Stent is indicated for the non-emergency treatment of pulmonary artery stenosis in pediatric patients who are at least 10kg in weight with two ventricle anatomy. The PALMAZ MULLINS XD™ Pulmonary Stent is a balloon-expandable, laser cut stent made from 316L stainless steel tubing. The stent is supplied unmounted and in five (5) nominal unexpanded lengths: 19 mm, 25 mm, 29 mm, 39 mm, and 59 mm.

06

What researchers measure

Primary outcomes

  1. Technical Success (Successful use of the study device without additional, unplanned device or procedure-related surgery/re-intervention)

    1. Successful access, delivery and retrieval of the device delivery system, 2. Deployment and correct positioning of the device in the intended location, and 3. No need for additional, unplanned surgery or re-intervention related to the device or access procedure.

    Time frame: Start time of index procedure through time of discharge/study completion, usually within ~48 hours from end time of index procedure

  2. Patency (Angiographically-determined increase in stented vessel minimum pulmonary artery diameter by ≥ 50% of the pre-stent diameter)

    Increase in stented vessel minimum pulmonary artery diameter by ≥ 50% of the pre-stent diameter determined by post-implant angiography.

    Time frame: Index procedure (start time to end time)

  3. Safety Outcome (Incidence of Treatment-Emergent Serious Adverse Events)

    Device or procedure-related, serious adverse events reported through time of hospital discharge, which meet any of the following criteria: 1. Led to a death, 2. Led to a serious deterioration in health of the subject, that either resulted in 1. Life-threatening illness or injury, or 2. Hospitalization (initial or prolonged) or 3. Disability or permanent impairment of a body structure or a body function or 4. Medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function 3. Other Serious (important) Medical Events

    Time frame: Time of enrollment (device implant during index procedure) through time of discharge/study completion, usually within ~48 hours from end time of index procedure

Other outcomes

  1. Baseline Characteristics - Demographics

    Demographics (age, gender)

    Time frame: Pre-procedure baseline

  2. Baseline Characteristics - Medical History

    Medical History (diagnosis, prior surgery)

    Time frame: Pre-procedure baseline

  3. Baseline Characteristics - Clinical History: Weight

    Clinical History (weight in kg)

    Time frame: Pre-procedure baseline

  4. Baseline Characteristics - Clinical History: Height

    Clinical History (height in cm)

    Time frame: Pre-procedure baseline

  5. Baseline Characteristics - Clinical History: Body Surface Area

    Clinical History (body surface area in square meters)

    Time frame: Pre-procedure baseline

  6. Target Vessel Characteristics (Stenosis type and location, lesion length and target vessel diameters)

    Stenosis type and location, lesion length and target vessel diameters

    Time frame: Angiography during index procedure

  7. Procedural Characteristics (occurrence and outcomes of pre-dilation, stent deployment and post-dilation during index procedure)

    Occurrence and outcomes of pre-dilation, stent deployment and post-dilation during index procedure

    Time frame: Index procedure

  8. Device Characteristics - Dimensions of PALMAZ MULLINS XD™ Pulmonary Stent

    PALMAZ MULLINS XD™ Pulmonary Stent dimensions

    Time frame: Index procedure

  9. Device Characteristics - Balloon Manufacturer/Model and Dimensions

    Balloon manufacturer/model and dimensions

    Time frame: Index procedure

  10. Device Characteristics - Sheath Manufacturer/Model and Dimensions

    Sheath manufacturer/model and dimensions

    Time frame: Index procedure

07

Study locations

3 of 8 sites recruiting
  • UC Davis Children's Hospital
    Sacramento, California 95817, United States
    Not yet recruiting
    • Frank Ing, MD · Contact
    • Frank Ing, MD · Principal investigator
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30329, United States
    Not yet recruiting
    • Jimmy Kuo, MD · Contact
    • Jimmy Kuo, MD · Principal investigator
  • Children's Hospital of Michigan
    Detroit, Michigan 48201, United States
    Recruiting
    • Neha Ahluwalia, MD · Contact
    • Neha Ahluwalia, MD · Principal investigator
  • St Louis Children's Hospital
    St Louis, Missouri 63110, United States
    Not yet recruiting
    • Dominic Zanaboni, MD · Contact
    • Dominic Zanaboni, MD · Principal investigator
  • University of Nebraska Medical Center
    Omaha, Nebraska 68114, United States
    Recruiting
    • Jeffrey Delaney, MD · Contact
    • Jeffrey Delaney, MD · Principal investigator
  • Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
    Recruiting
    • Shabana Shahanavaz, MD · Contact
    • Shabana Shahanavaz, MD · Principal investigator
  • UMPC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
    Not yet recruiting
    • Bryan Goldstein, MD · Contact
    • Bryan Goldstein, MD · Principal investigator
  • Texas Children's Hospital
    Houston, Texas 77030, United States
    Not yet recruiting
    • Asra Khan, MD · Contact
    • Asra Khan · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Dec 2025 → Jun 2026, primary completion Dec 2027 → Jun 2028 and completion Dec 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Aug 14, 2025
StartActual
Jun 23, 2026was Dec 2025
Primary completionEst.
Jun 2028was Dec 2027
CompletionEst.
Jun 2028was Dec 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
8 sites added — first site in United States
Show 8 added (8 United States)
  • UC Davis Children's Hospital · Sacramento, United States
  • Children's Healthcare of Atlanta · Atlanta, United States
  • Children's Hospital of Michigan · Detroit, United States
  • St Louis Children's Hospital · St Louis, United States
  • University of Nebraska Medical Center · Omaha, United States
  • Children's Hospital Medical Center · Cincinnati, United States
  • UMPC Children's Hospital of Pittsburgh · Pittsburgh, United States
  • Texas Children's Hospital · Houston, United States
Oct 2, 2026
Start date
Dec 2025→Jun 23, 2026 (actual)
Oct 2, 2026
Primary completion
Dec 2027→Jun 2028
Oct 2, 2026
Study completion
Dec 2027→Jun 2028
Oct 2, 2026
Enrollment
75→35
Oct 2, 2026
Eligibility
Maximum age 21 Years→none; 1 criterion edited
What changed in the criteria
  • Edited- Subjects *should* meet criteria as per the list of indications/contraindications in the Instructions for Use, though all subjects treated with the PALMAZ MULLINS XD™ Pulmonary Stent will be considered eligible and enrolled.
Oct 2, 2026
Contact
Study contact changed: added r•••@cordis.com. See the current contact
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Recruiting
    8 sites added — first site in United States
    Show 8 added (8 United States)
    • UC Davis Children's Hospital · Sacramento, United States
    • Children's Healthcare of Atlanta · Atlanta, United States
    • Children's Hospital of Michigan · Detroit, United States
    • St Louis Children's Hospital · St Louis, United States
    • University of Nebraska Medical Center · Omaha, United States
    • Children's Hospital Medical Center · Cincinnati, United States
    • UMPC Children's Hospital of Pittsburgh · Pittsburgh, United States
    • Texas Children's Hospital · Houston, United States
    Start date Dec 2025→Jun 23, 2026 (now actual)
    Primary completion Dec 2027→Jun 2028
    Study completion Dec 2027→Jun 2028
    Enrollment 75→35
    Eligibility Maximum age 21 Years→none; 1 criterion edited
    What changed in the criteria
    • Edited- Subjects *should* meet criteria as per the list of indications/contraindications in the Instructions for Use, though all subjects treated with the PALMAZ MULLINS XD™ Pulmonary Stent will be considered eligible and enrolled.
    Contact Study contact changed: added r•••@cordis.com. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07122518
Lead sponsor
Cordis US Corp.
Collaborators
Congenital Cardiovascular Interventional Study Consortium (CCISC)
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Jun 23, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Jenny Jimenez
Contact
jenny.jimenez@cordis.com
1 669-255-4123
Rajesh Nathan
Contact
rajesh.nathan@cordis.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion